News AZ builds in China, as J&J ramps up its US investments AstraZeneca will open its sixth R&D centre in China, while J&J announces four new manufacturing facilities in the US in a major reshoring drive.
News J&J adds to IL-23 options in Crohn's after FDA approval J&J's Tremfya gets a much-anticipated FDA approval for Crohn's disease, which the company thinks will be key to a renewed phase of sales growth.
News J&J's nipocalimab fast-tracked for Sjogren's disease Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjogren's disease.
News J&J abandons work with Genmab on Darzalex successor Genmab is facing increased pressure to deliver on its in-house pipeline after Johnson & Johnson exited a partnership on a Darzalex follow-up.
News J&J shows its confidence in oral IL-23 drug for psoriasis J&J wants to turn the screw in the psoriasis market with a new head-to-head trial pitting oral IL-23 drug icotrokinra against Stelara.
News One of J&J's blockbuster depression hopes has flamed out Johnson & Johnson has halted the development of aticaprant as a treatment for major depressive disorder, blowing a hole in its late-stage pipeline.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl